Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 10/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.67 |
| ▸ | JUN | P05412 | 8/20 | 0.67 |
| ▸ | CDK2 | P24941 | 7/20 | 0.67 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.51 |
| ▸ | DKK1 | O94907 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646457 | 0.94 | MAPK8 (0.60) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3649000 | 0.94 | MAPK8 (0.60) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3647354 | 0.87 | CYP11B2 (0.58) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3652055 | 0.87 | CYP11B2 (0.59) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3647557 | 0.86 | MAPK10 (0.55) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3650663 | 0.86 | JUN (0.50) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3653157 | 0.85 | HDAC8 (0.55) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3772849 | 0.85 | DGAT1 (0.54) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3643785 | 0.84 | CDK2 (0.53) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL3652907 | 0.84 | HDAC8 (0.52) | MAPK8MAPK9JUNCDK2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| EP-2190824-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | Wyeth a Corporation of the State of Delaware (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | MAPK8 170/4885MAPK9 1596/4885JUN 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.